Description

Retatrutide (LY3437943)

Retatrutide (internally designated as LY3437943) represents the newest frontier in multi-receptor pharmacology. It is a synthetic 39-amino acid peptide that functions as a powerful triple agonist, simultaneously targeting the Glucagon-Like Peptide-1 (GLP-1) receptor, the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor, and the Glucagon receptor (GCGR). In advanced metabolic and obesity research, Retatrutide is uniquely distinguished by its integration of the glucagon receptor pathway. By activating GCGR, it stimulates energy expenditure and promotes hepatic lipid metabolism, which, when combined with the glycemic control of GLP-1 and GIP, providing researchers with a non-linear model for investigating weight loss and metabolic remodeling.

Research Applications & Mechanisms

Triple-Receptor Synergy (GLP-1/GIP/GCGR)

Investigating the potentiation of metabolic signaling when the glucagon receptor is activated alongside incretin receptors to increase basal metabolic rate.

Thermogenesis & Energy Expenditure

Researching the molecular pathways through which Retatrutide stimulates thermogenesis and fat oxidation in experimental metabolic models.

Hepatic Fat Mobilization

Studying the influence of GCGR activation on liver lipid homeostasis and its potential in metabolic dysfunction-associated steatohepatitis (MASH) research.

Advanced Glycemic Homeostasis

Exploring the complex interplay between triple-agonism and pancreatic beta-cell stability for superior glucose regulation in research models.

Technical Specifications